Review Article

Receptor tyrosine kinase signaling pathways: a review

Nikhil Pathi, Sundaram Viswanath, Abhishek Pathak*, Anvesh Rathore,
Abhishek Prukayastha

Department of Medical Oncology, Army Hospital Research and Referral, New Delhi, India

Received: 02 August 2016

Revised: 20 August 2016

Accepted: 06 September 2016

*Correspondence:

Dr. Abhishek Pathak,

E-mail: drabhipat@gmail.com

Copyright: © the author(s), publisher and licensee Medip Academy. This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

ABSTRACT

The two important enabling characteristics of cancer cells are uncontrolled proliferation and loss of programmed cell death (enhanced survival). These processes are tightly controlled by the discrete integration of signalling cascades that translate extracellular and intracellular cues into specific output responses. Alterations in these pathways in cancer cells by mutation, amplification/deletion, chromosomal translocation, over expression, or epigenetic silencing lead to constitutive activation or suppression of signalling. We will review the major signal transduction cascade well known as the receptor tyrosine kinase pathway, focussing on their common alterations in human cancers and their clinical implications and therapeutics. Since major drug development efforts are presently being focused on the development of targeted inhibitors of oncogene-activated signalling pathways, a detailed understanding of these normal physiological pathways along with their deregulation in cancer will be required of both basic cancer researchers and practicing clinical oncologists for betterment of mankind suffering. Hence with this requirement in mind we have written this article to highlight some of the most important signal transduction pathways that is receptor tyrosine signalling pathways.

Keywords: EGFR, PDGFR, Receptor tyrosine kinase pathways

INTRODUCTION

The two important enabling characteristics of cancer cells are uncontrolled proliferation and loss of programmed cell death (enhanced survival). These processes are tightly controlled by the discrete integration of signaling cascades that translate extracellular and intracellular cues into specific output responses. The signaling pathways are often initiated on binding of ligand to the extracellular domain of a receptor. This is followed by recruitment of adaptor proteins or kinases that activate an intracellular cascading network of protein and lipid intermediaries producing a cellular response. Alterations in these pathways in cancer cells by mutation, amplification/deletion, chromosomal translocation, over expression, or

epigenetic silencing lead to constitutive activation or suppression of signaling. We will review the major signal transduction cascade well known as the receptor tyrosine kinase pathway, focussing on their common alterations in human cancers and their clinical implications and therapeutics.

Receptor tyrosine kinase signaling

Receptor tyrosine kinases (RTK) include a family of transmembrane cell surface receptors that transduce extracellular signals internally in to the cell. These play a role in cell growth, survival and/or cellular phenotypes.^{1,2} Growth factors bind to the extracellular ligand binding domain of RTKs and induce dimerization of two receptor

monomers, juxtaposing the intracellular tyrosine kinase domains of each monomer.^{3,4} This dimerization results in transphosphorylation of tyrosine residues within the cytoplasmic domains. They recruit a variety of intracellular proteins through Src homology 2 (SH2) domains.⁵ Each domain is part of a larger adaptor protein. Recruitment of signaling intermediaries to the plasma membrane facilitates their interaction with membrane-bound proteins responsible for stimulating a diverse array of downstream pathways. Approximately 20 classes of RTKs have been defined based on growth factor specificity.

Epidermal growth factor receptor signaling

In 1978, the epidermal growth factor receptor (EGFR) was identified as the cell surface binding site for EGF.⁶ Subsequently tyrosine phosphorylation was identified, which had potential implication in oncogenesis.^{7,8} The amino acid sequence of EGFR was homologous to the avian erythroblastosis virus erbB oncogene, which potentially induces erythroleukemia.^{9,10} The EGFR class of RTKs comprises four receptor proteins encoded by four genes: EGFR (ERBB1), HER2/neu (ERBB2), HER3 (ERBB3), and HER4 (ERBB4). Clinically important EGFR ligands include EGF, transforming growth factor (TGF)- α and heparin-binding (HB)-EGF among many others.^{11,12} However specific ligand for HER2 has not yet been identified. HER2 is activated through heterodimer formation with other ligand-bound receptors preferably with EGFR.¹³ These heterodimers are more stable than EGFR homo dimers. They have a longer duration of action, a lower rate of endocytosis which slows dissociation of EGF from EGFR along with increased recycling to the cell surface.¹⁴⁻¹⁶

HER2-HER3 hetero dimers possess the most potent mitogenic activity among the other combinations.¹⁷ HER3 does not have intrinsic kinase activity and preferentially forms hetero dimers with HER2.¹⁸

EGFR mutations are found in 10% to 50% of non-small cell lung cancers. 80% of these are Kinase domain deletions (exon 19) and mutations (exon 21).^{19,20} Overexpression of wild-type EGFR due to gene amplification is seen in non-small cell lung, breast, gastric, colorectal, and head and neck cancers.^{21,22} HER over expression is seen in 30% of breast cancers.²³ In glioblastoma multiforme, the extracellular domain of EGFR is deleted expressing a constitutively activated truncated mutant protein (EGFRvIII).^{24,25}

Targeted agents include gefitinib and erlotinib, both of which are used for the treatment of non-small cell lung cancers that harbor activating EGFR kinase mutations.²⁶ Cetuximab, binds to the extracellular domain of EGFR and competitively inhibits ligand binding, is approved for the treatment of colorectal and head and neck cancers.²⁷⁻²⁹ Trastuzumab binds to the extracellular domain of HER2 is used in the treatment of breast cancers that display

HER2 overexpression. Pertuzumab binds to the dimerization domain resulting in impaired dimer formation.³⁰ Lapatinib is used in combination with capecitabine in HER2-overexpressing advanced or metastatic breast cancer who have progressed on trastuzumab and certain classes of chemotherapy.³¹

Mechanisms of resistance include overexpression of other HER kinase family members and/or ligands, phosphatase and tensin homolog (PTEN) loss, and the expression of a truncated HER2 protein lacking the extracellular antibody binding site.³² Addition of trastuzumab to chemotherapy compared with chemotherapy alone is associated with improved overall survival in patients with HER2-overexpressing esophagogastric cancer.³³

Insulin and insulin-like growth factor-1 receptor signaling

The insulin receptor exists as two isoforms.³⁴ The IGF1 receptor (IGF1R) can dimerize with either of the insulin receptor isoforms or with itself. The insulin receptor is stimulated by insulin or insulin-like growth factor-2 (IGF2), whereas IGF1R can be activated by either IGF1 or IGF2.^{35,36} After ligand binding, IGF1R dimerizes and undergoes transphosphorylation, leading to activation of downstream RAS-RAF-mitogen-activated protein kinase (MAPK) and the PI3K-AKT-mammalian target of rapamycin (mTOR) cascades.³⁷

Amplification of the IGF1R gene locus has been identified in colon, pancreatic, and lung cancers. Sarcomas often have either increased expression of the IGF1 and IGF2 ligands or decreased insulin-like growth factor binding protein-3 expression (Ewing sarcoma), which results in increased IGF1 levels in the tumor microenvironment.³⁸ Gastrointestinal stromal tumors (GISTs) lacking KIT and platelet-derived growth factor receptor (PDGFR) mutations also commonly harbor IGF1R amplification.³⁹ IGF1R overexpression has also been observed in up to 44% of breast tumors and may mediate resistance to HER2-directed therapies.⁴⁰

The insulin receptor family members anaplastic lymphoma kinase (ALK) and ROS1 were also recently implicated in tumorigenesis.^{41,42} In NSCLC, there is expression of an EML4- ALK fusion protein in 2% to 5% of patients.⁴³ Who often exhibit dramatic radiographic responses to crizotinib, an inhibitor of the ALK, ROS1, and MET tyrosine kinases.⁴⁴ EML-ALK fusions are found in a mutually exclusive pattern with EGFR kinase domain mutations.^{45,46}

Platelet-derived growth factor receptor signaling

PDGF signaling implicated in organ development, including lung, intestinal epithelial folding and glomerular capillary tuft formation. They also promote angiogenesis, wound healing, and erythropoiesis.⁴⁷ Four isoforms of PDGF have been identified: PDGF-A, -B, -C,

and -D.⁴⁸ Its receptor subtype PDGFR- α inhibit chemotaxis, whereas PDGFR- β stimulate chemotaxis within fibroblasts and smooth muscle cells.⁴⁹

Excess autocrine secretion of PDGF is noted in glioblastoma and sarcomas, while gain-of-function mutations that cause constitutive tyrosine kinase activation are seen in gastrointestinal stromal tumors.⁵⁰ Translocation of either the PDGF or PDGFR genes are found in dermatofibrosarcoma protuberans, chronic myelomonocytic leukemia, and hypereosinophilic syndrome) and PDGFR gene amplification are seen in glioblastoma.⁵¹⁻⁵⁴ PDGFR- α mutations are found in about 10% of KIT wild-type GISTs. The D842V mutation seen in about two thirds of PDGFR- α activating mutation is resistant to inhibition by imatinib. Dermatofibrosarcoma protuberans shows overexpression of PDGF- β and subsequent stimulation of PDGFR signaling.

Imatinib is also approved for use in patients with KIT mutant GISTs and Philadelphia chromosome-positive hematologic cancers.⁵⁵ The KIT RTK is a member of the type III RTK family that includes PDGFR and Fms- like tyrosine kinase-3 (FLT3).^{56,57} Stem cell factor (SCF) is the ligand for KIT.⁵⁸⁻⁶¹ Hot-spot mutations in exons 9 and 11 of KIT have been identified in GISTs and melanomas.⁶²⁻⁶⁵

The FLT3 receptor, a member of the RTK class is involved in the development of normal hematopoietic cells. Internal tandem duplication within exons 14 and 15 of the FLT3 gene is found in one third of acute myelogenous leukemias (AMLs) associated with a poor prognosis.⁶⁶

Fibroblast growth factor receptor signaling

Fibroblast growth factors (FGFs) bind to the extracellular domain of the FGFRs inducing FGFR dimerization and transphosphorylation of intracellular tyrosine residues and activation of multiple downstream signaling proteins in the same manner as previously described for other RTKs. Unique to the FGFR signaling complex is FGFR substrate 2 (FRS2), an adaptor protein that binds to specific phosphotyrosines on the intracellular domain also serving as a docking site for the Grb2-Sos adaptor complex which finally activates the RAS/RAF/MAPK pathway. It also activates PI3K/AKT/MTOR pathway by a different site specific interaction on docking protein.

Activating mutations within FGFR3 occur in up to 70% of non- muscle invasive bladder cancers and in 15% of patients with advanced urothelial tumors.^{66,67} FGFR3 mutations are commonly located within the extracellular domain and promote ligand-independent receptor dimerization through formation of an aberrant disulfide bridge between two receptor monomers stabilizing and activating the downstream complex.⁶⁸ Up to 15% of multiple myelomas harbor an intergenic 4;14 translocation between the FGFR3 gene and the

immunoglobulin heavy chain locus. Approximately 10% of diffuse-type gastric cancers display FGFR2 gene amplification.^{69,70} Autocrine and paracrine FGF ligand secretion has been reported to occur in a subset of melanomas and prostate cancers, respectively.^{71,72}

The close structural similarity between these RTKs has made development of FGFR selective inhibitors challenging. To date, anti-FGFR antibodies have not entered clinical testing, although preclinical studies have shown promising antitumor effects in urothelial cancer (both FGFR3 wild-type and mutant) and t (4;14) expressing multiple myeloma cell lines.⁷³

RET signaling

The RET (rearranged during transfection) protein is a RTK important for the normal development of the kidney and the enteric nervous system.^{74,75} RET is expressed predominantly on the surface of neural crest tissues, and glial-derived neurotrophic factors (GDNFs) serve as its ligands. Intracellular tyrosine residue specificity has sub functions like serving as a docking site for the STAT3 transcription factor, activation of focal adhesion kinase promoting cell migration and metastatic spread. Additional pathways diverging are MAPK, PI3K/ AKT, and phospholipase C- γ pathways which promote cellular proliferation and survival.⁷⁶

Germline RET mutations are the basis for the multiple endocrine neoplasia type 2 syndromes who are noted to develop familial medullary thyroid carcinomas.⁷⁷ Sporadic medullary thyroid carcinomas are much more common, and up to 60% of such tumors harbor somatic mutations in RET. Vandetanib, an oral inhibitor of RET, EGFR, and VEGFR, was recently approved by the FDA for the treatment of patients with advanced medullary thyroid cancer.⁷⁸ Cabozantinib, an oral, multitargeted TKI that inhibits RET, VEGFR2, and MNNG HOS transforming gene (MET) is being evaluated in unresectable, locally advanced, or metastatic medullary thyroid carcinoma.⁷⁹

Vascular endothelial growth factor signaling

Six vascular endothelial growth factor (VEGF) ligands have been identified, VEGF-A, -B, -C, and -D, along with placental growth factor 1 and 2.⁸⁰ VEGF-A enhances vascular permeability and stimulates endothelial cell proliferation, resulting in new blood vessel formation. VEGFRs are receptor tyrosine kinases that possess an extracellular domain with seven immunoglobulin-like regions, a transmembrane domain, and an intracellular tyrosine kinase domain. VEGF-A, VEGF-B, and placental growth factor all bind VEGFR1, but the exact role of VEGFR1 in tumor angiogenesis has yet to be fully elucidated. Evidence shows that it can act as a decoy receptor that prevents ligand-mediated stimulation of VEGFR2. VEGFR2 is considered the primary receptor through which VEGF exerts its angiogenic effects.⁸¹

Bevacizumab, by binding to free VEGF and blocking its association with VEGFR, has been approved in combination with chemotherapy in metastatic colorectal and nonsquamous NSCLCs.^{82,83} It has also clinically documented activity in glioblastoma and metastatic renal cell carcinoma.^{84,85} Sorafenib and sunitinib are multitargeted TKIs with nanomolar potency for VEGFR2. Sunitinib is used in the treatment of metastatic renal cell carcinoma, GISTs, and pancreatic neuroendocrine tumors.⁸⁶ Sorafenib has been approved for the treatment of liver and renal cell cancers.^{87,88} Pazopanib is approved for the initial treatment of metastatic renal cell carcinoma and in cytokine-pretreated patients, while axitinib is approved in the second-line setting after failure of prior systemic therapy.^{89,90}

Resistance mechanisms include the activation of redundant signaling pathways that promote angiogenesis, the recruitment by tumors of bone marrow derived endothelial progenitor cells, increased pericyte density around existing blood vessels that enhances vascular growth and survival, and the ability of tumor cells to invade surrounding stroma to co-opt additional blood supply.⁹¹

Hepatocyte growth factor receptor signaling

The hepatocyte growth factor receptor (HGFR or MET) is encoded by the MET gene.⁹² Upon binding of hepatocyte growth factor (HGF) to the extracellular portion of MET, receptor dimerization occurs, followed by transphosphorylation. Adaptor proteins like GRB2 and GAB1 promotes the activation of the MAPK and PI3K/AKT signaling pathways.⁹³ MET can also activate CDC42 and p21-activated kinase, concerned with regulation of cytoskeletal proteins, integrin expression and activation finally controlling cell migration.

EGFR activation can stimulate MET signaling, and resistance to EGFR inhibitors in some lung cancers is known to occur due to MET gene amplification.⁹⁴ Germline mutations of MET are found in hereditary papillary renal cell carcinomas. MET overexpression is observed in sporadic papillary cancers, as well as collecting duct carcinomas.⁹⁵ MET amplification is associated with a worse prognosis in lung and gastric cancers, and expression of MET and HGF are unfavorable prognostic biomarkers in liver, kidney, colorectal, and gastric cancers.⁹⁶ Studies suggest an improvement in progression-free survival with the addition of anti-MET antibodies to an EGFR inhibitor in patients whose tumors display MET overexpression.⁹⁷

CONCLUSION

We know that mutational and epigenetic alterations induce constitutive activation of a wide array of signaling pathways in human tumors. Since major drug development efforts are presently being focused on the development of targeted inhibitors of oncogene-activated

signaling pathways, a detailed understanding of these normal physiological pathways along with their dysregulation in cancer will be required of both basic cancer researchers and practicing clinical oncologists for betterment of mankind suffering. Hence with this requirement in mind we have written this article to highlight some of the most important signal transduction pathways i.e. receptor tyrosine signaling pathways.

Funding: No funding sources

Conflict of interest: None declared

Ethical approval: Not required

REFERENCES

1. Robinson DR, Wu YM, Lin SF. The protein tyrosine kinase family of the human genome. *Oncogene*. 2000;19:5548-57.
2. Schlessinger J. Cell signaling by receptor tyrosine kinases. *Cell*. 2000;103:211-25.
3. Hubbard SR, Till JH. Protein tyrosine kinase structure and function. *Annu Rev Biochem*. 2000;69:373-98.
4. Kuriyan J, Cowburn D. Modular peptide recognition domains in eukaryotic signaling. *Annu Rev Biophys Biomol Struct*. 1997;26:259-88.
5. Pawson T. Protein modules and signalling networks. *Nature*. 1995;373:573-80.
6. Carpenter G, King L, Cohen S. Epidermal growth factor stimulates phosphorylation in membrane preparations in vitro. *Nature*. 1978;276:409-10.
7. Eckhart W, Hutchinson MA, Hunter T. An activity phosphorylating tyrosine in polyoma T antigen immunoprecipitates. *Cell*. 1979;18:925-33.
8. Hunter T, Sefton BM. Transforming gene product of Rous sarcoma virus phosphorylates tyrosine. *Proc Natl Acad Sci*. 1980;77:1311-5.
9. Yamamoto T, Hihara H, Nishida T. A new avian erythroblastosis virus, AEV-H, carries erbB gene responsible for the induction of both erythroblastosis and sarcomas. *Cell*. 1983;34:225-32.
10. Downward J, Yarden Y, Mayes E. Close similarity of epidermal growth factor receptor and verb-B oncogene protein sequences. *Nature*. 1984;307:521-7.
11. Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. *Nat Rev Mol Cell Biol*. 2001;2:127-37.
12. Jones JT, Akita RW, Sliwkowski MX. Binding specificities and affinities of egf domains for ErbB receptors. *FEBS Lett*. 1999;447:227-31.
13. Klapper LN, Glathe S, Vaisman N. The ErbB-2/HER2 oncoprotein of human carcinomas may function solely as a shared coreceptor for multiple stroma-derived growth factors. *Proc Natl Acad Sci*. 1999;96:4995-5000.
14. Porta GD, Beerli RR, Daly JM. ErbB2, the preferred heterodimerization partner of all ErbB receptors, is a

- mediator of lateral signaling. *EMBO J*. 1997;16:1647-55.
15. Zaczek A, Brandt B, Bielawski KP. The diverse signaling network of EGFR, HER2, HER3 and HER4 tyrosine kinase receptors and the consequences for therapeutic approaches. *Histol Histopathol*. 2005;20:1005-15.
16. Worthylake R, Opresko LK, Wiley HS. ErbB-2 amplification inhibits down-regulation and induces constitutive activation of both ErbB-2 and epidermal growth factor receptors. *J Biol Chem* 1999;274:8865-74.
17. Okines A, Cunningham D, Chau I. Targeting the human EGFR family in esophagogastric cancer. *Nat Rev Clin Oncol*. 2011;8:492-503.
18. Kramarski PR, Soussan L, Waterman H. Diversification of Neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactions. *EMBO J*. 1996;15:2452-67.
19. Janne PA, Engelman JA, Johnson BE. Epidermal growth factor receptor mutations in non-small-cell lung cancer: implications for treatment and tumor biology. *J Clin Oncol*. 2005;23:3227-34.
20. Pao W, Miller V, Zakowski M. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. *Proc Natl Acad Sci*. 2004;101:13306-11.
21. Krause DS, Etten RA. Tyrosine kinases as targets for cancer therapy. *N Engl J Med*. 2005;353:172-87.
22. Hirsch FR, Garcia VM, Bunn PA. Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. *J Clin Oncol*. 2003;21:3798-807.
23. Slamon DJ, Clark GM, Wong SG. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. *Science*. 1987;235:177-82.
24. Wong AJ, Ruppert JM, Bigner SH. Structural alterations of the epidermal growth factor receptor gene in human gliomas. *Proc Natl Acad Sci*. 1992;89:2965-9.
25. Li B, Yuan M, Kim IA. Mutant epidermal growth factor receptor displays increased signaling through the phosphatidylinositol-3 kinase/AKT pathway and promotes radioresistance in cells of astrocytic origin. *Oncogene*. 2004;23:4594-602.
26. Lynch TJ, Bell DW, Sordella R. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. *N Engl J Med*. 2004;350:2129-39.
27. Cunningham D, Humblet Y, Siena S. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. *N Engl J Med*. 2004;351:337-45.
28. Saltz LB, Meropol NJ, Loehrer Sr PJ. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. *J Clin Oncol*. 2004;22:1201-8.
29. Bonner JA, Harari PM, Giralt J. Radio therapy plus cetuximab for squamous-cell carcinoma of the head and neck. *N Engl J Med*. 2006;354:567-78.
30. Geyer CE, Forster J, Lindquist D. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. *N Engl J Med*. 2006;355:2733-43.
31. Franklin MC, Carey KD, Vajdos FF. Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex. *Cancer Cell*. 2004;5:317-28.
32. Shojaei S, Gardaneh M, Shamabadi RA. Target points in trastuzumab resistance. *Int J Breast Cancer*. 2012;2012:761917.
33. Bang YJ, Van Cutsem E, Feyereislova A. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. *Lancet*. 2010;376:687-97.
34. Belfiore A, Frasca F, Pandini G. Insulin receptor isoforms and insulin receptor/insulin-like growth factor receptor hybrids in physiology and disease. *Endocr Rev*. 2009;30:586-623.
35. Jones JJ, Clemmons DR. Insulin-like growth factors and their binding proteins: biological actions. *Endocr Rev*. 1995;16:33-4.
36. Meyts P, Whittaker J. Structural biology of insulin and IGF1 receptors: implications for drug design. *Nat Rev Drug Discov*. 2002;1:769-83.
37. Nakae J, Kido Y, Accili D. Distinct and overlapping functions of insulin and IGF-I receptors. *Endocr Rev*. 2001;22:818-35.
38. Gombos A, Metzger FO, Dal LL. Clinical development of insulin-like growth factor receptor-1 (IGF-1R) inhibitors: At the crossroad? *Invest New Drugs*. 2012;30:2433-42.
39. Tarn C, Rink L, Merkel E. Insulin-like growth factor 1 receptor is a potential therapeutic target for gastrointestinal stromal tumors. *Proc Natl Acad Sci*. 2008;105:8387-92.
40. Shimizu C, Hasegawa T, Tani Y. Expression of insulin-like growth factor 1 receptor in primary breast cancer: immune histochemical analysis. *Hum Pathol*. 2004;35:1537-42.
41. Riethmacher SE, Walter B, Acher D. The cros tyrosine kinase receptor controls regionalization and differentiation of epithelial cells in the epididymis. *Genes Dev*. 1996;10:1184-93.
42. Camidge DR, Doebele RC. Treating ALK-positive lung cancer early successes and future challenges. *Nat Rev Clin Oncol*. 2012;9:268-77.
43. Soda M, Choi YL, Enomoto M. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. *Nature*. 2007;448:561-6.
44. Kwak EL, Bang YJ, Camidge DR. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. *N Engl J Med*. 2010;363:1693-703.

45. Bergethson K, Shaw AT, Ou SH. ROS1 rearrangements define a unique molecular class of lung cancers. *J Clin Oncol*. 2012;30:863-70.
46. Davies KD, Le AT, Theodoro MF. Identifying and targeting ROS1 gene fusions in non-small cell lung cancer. *Clin Cancer Res*. 2012;18:4570-9.
47. Heldin CH, Westermark B. Mechanism of action and in vivo role of platelet derived growth factor. *Physiol Rev*. 1999;79:1283-316.
48. Heldin CH, Eriksson U, Ostman A. New members of the platelet-derived growth factor family of mitogens. *Arch Biochem Biophys*. 2002;398:284-90.
49. Ostman A, Heldin CH. PDGF receptors as targets in tumor treatment. *Adv Cancer Res*. 2007;97:247-74.
50. Corless CL, Schroeder A, Griffith D. Mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib. *J Clin Oncol*. 2005;23:5357-64.
51. Carroll M, Tomasson MH, Barker GF. The TEL/platelet-derived growth factor beta receptor (PDGF beta R) fusion in chronic myelomonocytic leukemia is a transforming protein that self-associates and activates PDGF beta R kinase-dependent signaling pathways. *Proc Natl Acad Sci*. 1996;93:14845-50.
52. McArthur GA. Dermato fibrosarcoma pro tuberans: a surgical disease with a molecular savior. *Curr Opin Oncol*. 2006;18:341-6.
53. Cools J, DeAngelo DJ, Gotlib J. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. *N Engl J Med*. 2003;348:1201-14.
54. Fleming TP, Saxena A, Clark WC. Amplification and/or overexpression of platelet-derived growth factor receptors and epidermal growth factor receptor in human glial tumors. *Cancer Res*. 1992;52:4550-3.
55. Demetri GD, Mehren M, Blanke CD. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. *N Engl J Med*. 2002;347:472-80.
56. Andre C, Hampe A, Lachaume. Sequence analysis of two genomic regions containing the KIT and the FMS receptor tyrosine kinase genes. *Genomics*. 1997;39:216-26.
57. Yarden Y, Kuang WJ, Feng YT. Human proto oncogene c-kit: a new cell surface receptor tyrosine kinase for an unidentified ligand. *EMBO J*. 1987;6:3341-51.
58. Huang E, Nocka K, Beier DR. The hematopoietic growth factor KL is encoded by the Sl locus and is the ligand of the c-kit receptor, the gene product of the W locus. *Cell*. 1990;63:225-33.
59. Mol CD, Dougan DR, Schneider TR. Structural basis for the autoinhibition and STI-571 inhibition of c-Kit tyrosine kinase. *J Biol Chem*. 2004;279:31655-63.
60. Lev S, Yarden Y, Givol D. Dimerization and activation of the kit receptor by monovalent and bivalent binding of the stem cell factor. *J Biol Chem*. 1992;267:15970-7.
61. Antonescu CR. The GIST paradigm: lessons for other kinase-driven cancers. *J Pathol*. 2011;223:251-61.
62. Corless CL, Barnett CM, Heinrich MC. Gastrointestinal stromal tumours: origin and molecular oncology. *Nat Rev Cancer*. 2011;11:865-78.
63. Hirota S, Isozaki K, Moriyama Y. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. *Science*. 1998;279:577-80.
64. Kindblom LG, Remotti HE, Aldenborg F. Gastrointestinal pacemaker cell tumor (GIPACT): gastrointestinal stromal tumors show phenotypic characteristics of the interstitial cells of Cajal. *Am J Pathol*. 1998;152:1259-69.
65. Fletcher JA, Rubin BP. KIT mutations in GIST. *Curr Opin Genet Dev*. 2007;17:3-7.
66. Leung AY, Man CH, Kwong YL. FLT3 inhibition: a moving and evolving target in acute myeloid leukaemia. *Leukemia*. 2013;27(2):260-8.
67. Turner N, Grose R. Fibroblast growth factor signalling: from development to cancer. *Nat Rev Cancer*. 2010;10:116-29.
68. Pierrot BI, Brams A, Larde DC. Oncogenic properties of the mutated forms of fibroblast growth factor receptor 3b. *Carcinogenesis*. 2006;27:740-7.
69. Sibley K, Fenton JA, Dring AM. A molecular study of the t(4;14) in multiple myeloma. *Br J Haematol*. 2002;118:514-20.
70. Takeda M, Arao T, Yokote H. AZD2171 shows potent antitumor activity against gastric cancer overexpressing fibroblast growth factor receptor 2/keratinocyte growth factor receptor. *Clin Cancer Res*. 2007;13:3051-7.
71. Wang Y, Becker D. Antisense targeting of basic fibroblast growth factor and fibroblast growth factor receptor-1 in human melanomas blocks intratumoral angiogenesis and tumor growth. *Nat Med*. 1997;3:887-93.
72. Memarzadeh S, Xin L, Mulholland DJ. Enhanced paracrine FGF10 expression promotes formation of multifocal prostate adenocarcinoma and an increase in epithelial androgen receptor. *Cancer Cell*. 2007;12:572-85.
73. Qing J, Du X, Chen Y. Antibody based targeting of FGFR3 in bladder carcinoma and (4;14) positive multiple myeloma in mice. *J Clin Invest*. 2009;119:1216-29.
74. Costantini F, Shakya R. GDNF/Ret signaling and the development of the kidney. *Bioassays*. 2006;28:117-27.
75. Taraviras S, Gutierrez CV, Durbec P. Signalling by the RET receptor tyrosine kinase and its role in the development of the mammalian enteric nervous system. *Development*. 1999;126:2785-97.

76. Wells SA, Santoro M. Targeting the RET pathway in thyroid cancer. *Clin Cancer Res*. 2009;15:7119-23.
77. Mulligan LM, Kwok JB, Healey CS. Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A. *Nature*. 1993;363:458-60.
78. Wells SA, Robinson BG, Gagel RF. Van detanib in patients with locally advanced or meta- static medullary thyroid cancer: a randomized, double-blind phase III trial. *J Clin Oncol*. 2012;30:134-41.
79. Kurzrock R, Sherman SI, Ball DW. Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer. *J Clin Oncol*. 2011;29:2660-6.
80. Ferrara N, Gerber HP, Lecouter J. The biology of VEGF and its receptors. *Nat Med*. 2003;9:669-76.
81. Ferrara N. Vascular endothelial growth factor: basic science and clinical progress. *Endocr Rev*. 2004;25:581-611.
82. Hurwitz H, Fehrenbacher L, Novotny W. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. *N Engl J Med*. 2004;350:2335-42.
83. Sandler A, Gray R, Perry MC. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. *N Engl J Med*. 2006;355:2542-50.
84. Vredenburgh JJ, Desjardins A, Herndon JE. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. *J Clin Oncol*. 2007;25:4722-9.
85. Escudier B, Pluzanska A, Koralewski P. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. *Lancet*. 2007;370:2103-11.
86. Chow LQ, Eckhardt SG. Sunitinib: from rational design to clinical efficacy. *J Clin Oncol*. 2007;25:884-96.
87. Kane RC, Farrell AT, Madabushi R. Sorafenib for the treatment of unresectable hepatocellular carcinoma. *Oncologist*. 2009;14:95-100.
88. Escudier B, Eisen T, Stadler WM. Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. *J Clin Oncol*. 2009;27:3312-8.
89. Sternberg CN, Davis ID, Mardiak J. Pazo panib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. *J Clin Oncol*. 2010;28:1061-8.
90. Rini BI, Escudier B, Tomczak P. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. *Lancet*. 2011;378:1931-9.
91. Loges S, Schmidt T, Carmeliet P. Mechanisms of resistance to anti-angiogenic therapy and development of third-generation anti-angiogenic drug candidates. *Genes Cancer*. 2010;1:12-25.
92. Bottaro DP, Rubin JS, Faletto DL. Identification of the hepatocyte growth factor receptor as the cmet proto-oncogene product. *Science*. 1991;251:802-4.
93. Furge KA, Zhang YW, Woude GF. Met receptor tyrosine kinase: enhanced signaling through adapter proteins. *Oncogene*. 2000;19:5582-9.
94. Engelman JA, Zejnullahu K, Mitsudomi T. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. *Science*. 2007;316:1039-43.
95. Schmidt L, Duh FM, Chen F. Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. *Nat Genet*. 1997;16:68-73.
96. Peters S, Adjei AA. MET: a promising anticancer therapeutic target. *Nat Rev Clin Oncol*. 2012;9:314-26.
97. Spigel D, Ervin, TJ, Ramlau R. Final efficacy results from OAM4558g, a randomized phase II study evaluating MetMab or placebo in combination with erlotinib in advanced NSCLC. *J Clin Oncol*. 2011;29.

Cite this article as: Pathi N, Viswanath S, Pathak A, Rathore A, Prukayastha A. Receptor tyrosine kinase signaling pathways: a review. *Int J Adv Med* 2016;3:783-9.